Health Care International - Metabasis Announces Promising Results From Its Phase 1b Clinical Trial For MB07811, Its Novel Product Candidate For The Treatment Of Hyperlipidemia
Metabasis Therapeutics, Inc. (Nasdaq:MBRX) announced the results of its 14-day, Phase 1b multiple-dose clinical trial in subjects with mild hypercholesterolemia, which showed that MB07811 was safe and well tolerated across the seven doses tested, ra
Comments